This Guidance Note outlines some key tax implications of Brexit on the pharmaceutical industry. The implications for the future framework for Customs Duty will be of upmost significance but the impact on VAT and, to some extent, Corporation Tax will also be of importance.
This Note does not cover every aspect of UK and international taxation that could be affected but draws out those considered to be of greatest significance for the Life Sciences sector.
This content is restricted to members. To view this content please register or login below to view this content.